CLINICAL TRIAL: RITUXAN/BEAM VS BEXXAR/BEAM FOR DIFFUSE LARGE B CELL NON-HODGKI

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 主要目的是比较两个移植组之间的PFS。 次要目的是比较两组之间的总生存期、至疾病进展时间、第100天的CR和PR比例、至造血恢复时间、血液学功能、感染发生率、第+21天的最大粘膜炎评分、免疫重建、治疗相关死亡率、骨髓增生异常综合征（MDS）、继发性急性髓性白血病（AML）或异常细胞遗传学的发生率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to compare PFS between the two transplant arms. Secondary objectives are to compare overall survival, time to progression, CR and PR proportion at Day 100, time to hematopoietic recovery, hematologic function, incidence of infection, maximum mucositis score by Day +21, immune reconstitution, treatment-related mortality, incidence of myelodysplastic syndrome (MDS), secondary acute myelogenous leukemia (AML), or abnormal cytogenetics between the two arms.